Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manige Konig

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|December 8, 2011
The genetic interface between gestational diabetes and type 2 diabetesManige Konig, Alan R Shuldiner
AACE Clinical Case Reports|January 23, 2020
A UNIQUE CASE OF CENTRAL HYPOPITUITARISM AND CENTRAL DIABETES INSIPIDUS CAUSED BY DIFFUSE LARGE B-CELL LYMPHOMAJason A Stegink, Vishal Sehgal, Manige Konig
Diabetes, Obesity & Metabolism|November 3, 2020
Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE studyKristina Boye, Melissa Ross, Reema Mody, et al.
Diabetes, Obesity & Metabolism|September 18, 2020
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world dataReema Mody, Maria Yu, Bal Nepal, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With CalcitriolElizabeth A Streeten, Yasaman Mohtasebi, Manige Konig, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 13, 2019
Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled AnalysisHiren Patel, Kashif Munir, Sindee Sutherland, et al.
Current Diabetes Reviews|July 20, 2013
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?Manige Konig, Elizabeth Mary Lamos, Stephanie Aleskow Stein, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 21, 2022
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective StudyRadhika Nair, Reema Mody, Maria Yu, et al.
Journal of Clinical Pharmacology|October 19, 2023
Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of DulaglutideCheng Cai Tang, Jean Lim, Li Shen Loo, et al.
Diabetes Care|January 19, 2022
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND TrialAnita Y M Kwan, Hertzel C Gerstein, Jan Basile, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|December 8, 2011
The genetic interface between gestational diabetes and type 2 diabetesManige Konig, Alan R Shuldiner
AACE Clinical Case Reports|January 23, 2020
A UNIQUE CASE OF CENTRAL HYPOPITUITARISM AND CENTRAL DIABETES INSIPIDUS CAUSED BY DIFFUSE LARGE B-CELL LYMPHOMAJason A Stegink, Vishal Sehgal, Manige Konig
Diabetes, Obesity & Metabolism|November 3, 2020
Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE studyKristina Boye, Melissa Ross, Reema Mody, et al.
Diabetes, Obesity & Metabolism|September 18, 2020
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world dataReema Mody, Maria Yu, Bal Nepal, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2017
Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With CalcitriolElizabeth A Streeten, Yasaman Mohtasebi, Manige Konig, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 13, 2019
Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled AnalysisHiren Patel, Kashif Munir, Sindee Sutherland, et al.
Current Diabetes Reviews|July 20, 2013
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?Manige Konig, Elizabeth Mary Lamos, Stephanie Aleskow Stein, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 21, 2022
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective StudyRadhika Nair, Reema Mody, Maria Yu, et al.
Journal of Clinical Pharmacology|October 19, 2023
Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of DulaglutideCheng Cai Tang, Jean Lim, Li Shen Loo, et al.
Diabetes Care|January 19, 2022
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND TrialAnita Y M Kwan, Hertzel C Gerstein, Jan Basile, et al.
Pageof 3